ODTC   $1.8  0.0 Market Closed

Last Events:

2023-03-29 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-03-29 Signal in EMA100 changed from bullish reversal to n/a. 2022-08-18 the price crossed up the moving average line and demonstrates an upside trend.

2023-03-29 Signal in EMA20 changed from bearish reversal to bullish reversal. 2023-02-02 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.

2023-03-29 Trend Power changed from strong to .

2023-03-29 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA100 changed from n/a to bullish reversal. 2023-02-21 the price crossed up the moving average line and getting closer to the MA, which means that the short-term upside trend weakens.

2023-03-29 Signal in EMA20 changed from bullish reversal to bearish reversal. 2023-03-07 the price crossed down the moving average line and formed a short-term downside trend.

2023-03-29 Trend Power changed from to strong.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy Buy Buy
rsi ActivelyBuy ActivelyBuy Sell
macd - - -
stoch - - -
ma20 - Sell ActivelyBuy
ma50 - - -
ma100 ActivelyBuy Buy -
Candlestick PatternMarch 8, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US6760791060
ceo Mr. Kevin C. Tang
Website https://www.odonate.com
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.